Tericke D. Blanchard is a health policy manager in global public policy for Wyeth Pharmaceuticals where he is responsible for the analysis of regulatory and legislative issues. In this role, he also chairs the Clinical Trials Policy Working Group which facilitates the company’s response to the National Institutes of Health regarding clinical trial registry and reporting procedures. Prior to joining Wyeth, he was an editor in the health science division of Elsevier. Tericke earned his BA from Harvard College and an International MBA from the Fox School of Business, Temple University that included residences in Paris, Philadelphia, and Tokyo.
Tericke will spend his fellowship in Tokyo conducting research on Japanese policies and regulations governing the pharmaceutical industry. While Japan is the second largest pharmaceutical market in the world, there have been several obstacles that have delayed the availability of medical products. His research will examine a 2008 government initiative that emphasizes medical innovation. Tericke will look to assess these changes and their potential impact on Japanese public health and the country’s competitiveness.
Membership Application Deadlines: November 1 and March 1
Term Membership Application Deadline: January 3, 2017
Membership in the CFR Corporate Program is tailored to meet the needs of your organization. To learn more, please visit the About Corporate page, view a printable brochure, and see our current list of members.
To find out if Corporate membership would benefit your company, contact the Corporate Program at email@example.com or 212.434.9684.
Published by the Council on Foreign Relations since 1922
CFR offers exceptional opportunities for individuals at all levels in their careers.Foreign Affairs Job Board
Search the ultimate resource for careers in international affairs.
Learn more about CFR’s mission and its work over the past year in the 2016 Annual Report. The Annual Report spotlights new initiatives, high-profile events, and authoritative scholarship from CFR experts, and includes a message from CFR President Richard N. Haass.
Read and download »